Committee Mark Up Targets Brand Name Drug Companies’ Anti-Competitive Tactics That Undermine More Affordable Alternatives
For Immediate Release
Contact: Jon Conradi
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement today in advance of a U.S. House of Representatives Committee on the Judiciary mark up of two bills that would crack down on the pharmaceutical industry’s patent abuse and promote competition in the pharmaceutical market.
“CSRxP commends Chairman Nadler and members of the Judiciary Committee for taking up important solutions that will hold Big Pharma accountable and help stop brand name drug companies from gaming the system to undermine competition,” said CSRxP executive director Lauren Aronson. “CSRxP encourages committee members to advance these bills that will crack down on Big Pharma’s anti-competitive tactics like product hopping and add to the momentum in Washington to lower prescription drug prices.”
The following bills being heard before the Committee on the Judiciary are supported by CSRxP:
Learn more on market-based solutions to hold Big Pharma accountable and lower prescription drug prices HERE.